Fig. 2.

ITGA6 was significantly upregulated in BC and correlated with the prognosis of BC patients.

a, b Western blotting (left) of METTL3 (a) and ITGA6 (b) in bladder cancer cells. The chart (right) shows the relative ITGA6 integrated density in the Western blotting results. * p < .05, ** p < .01, *** p < .001, **** p < .0001. (one-way ANOVA, Dunnett ‘s test). c RT-qPCR analysis of ITGA6 mRNA expression in bladder cancer cells compared with that in SV-HUC-1 cells. d, e ITGA6 (d) and METTL3 (e) expression in bladder cancer patient tumour microarrays (TMAs). Representative images of IHC staining for ITGA6 and METTL3 in tumour and paratumour tissues of TMAs. Bar = 200 μm, 50×. Bar = 50 μm, 400×. The graph (right) shows that ITGA6 and METTL3 were significantly upregulated in bladder cancer TMAs. Tumour, n = 56. Paratumour, n = 10. ** p < .01, **** p < .0001. (Student's t-test). f Correlation analysis of ITGA6 and METTL3 expression in tissue microarrays; r = 0.4067, p = .0007. (Pearson's correlation analysis). g The Kaplan-Meier survival curve indicates that patients with high ITGA6 expression had low survival rates. h IHC staining of bladder cancer patient tumour samples revealed that the level of ITGA6 expression was positively correlated with histological grade and stage. The chart shows the statistical analysis of ITGA6 in bladder cancer clinical pathology sections. PUNLMP (papillary urothelial neoplasms of low malignant potential) = 4, Low-grade = 80, High-grade = 102. All bar plot data are the means ± SEMs of three independent experiments.